TRO 40303

Drug Profile

TRO 40303

Alternative Names: TRO-40303

Latest Information Update: 17 Aug 2015

Price : $50

At a glance

  • Originator Trophos
  • Class Cholestenones; Neuroprotectants; Oximes; Secosteroids; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial reperfusion injury

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 17 Aug 2015 Discontinued - Phase-II for Myocardial reperfusion injury (Prevention) in France, Denmark, Norway and Sweden (IV)
  • 01 Sep 2013 Trophos completes a phase II trial in Myocardial reperfusion injury (Prevention) in Denmark, France, Norway and Sweden (NCT01374321)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top